Get the Stockscreener App
24.39
0.53%
-0.13
After Hours:
24.42
0.03
+0.12%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.39, with a volume of 47.64M.
It is down -0.53% in the last 24 hours and up +1.75% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.52
Open:
$24.49
24h Volume:
47.64M
Relative Volume:
0.98
Market Cap:
$138.67B
Revenue:
$63.83B
Net Income/Loss:
$10.77B
P/E Ratio:
12.97
EPS:
1.8799
Net Cash Flow:
$12.44B
1W Performance:
-5.02%
1M Performance:
+1.75%
6M Performance:
+8.69%
1Y Performance:
-17.15%
1-Day Range:
$24.21
$24.58
1-Week Range:
$24.21
$25.90
52-Week Range:
$20.91
$29.82
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.39 | 139.41B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
826.57 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
191.17 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
226.22 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.97 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.11 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer CEO Says Vaccine Approvals Are Harder to Get Right Now - Bloomberg.com
Why Moderna Might Be a One-Hit Wonder - The Motley Fool
AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget
Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer - Barchart.com
GSK Fights Pfizer's Bid To Nix COVID-19 Vaccine Patents - Law360
Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts - MarketScreener
Pfizer touts Tukysa in front-line breast cancer after Phase III victory - Yahoo Finance
Pfizer touts new Phase III win for Tukysa in front-line breast cancer - The Pharma Letter
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Pfizer (PFE) CEO Advocates for Collaboration with China's Pharma Industry - GuruFocus
Pfizer (PFE) CEO Highlights China's Rapid Drug Development - GuruFocus
Pfizer CEO touts China's 'dramatic speed' in biopharma, calls for U.S. collaboration - Seeking Alpha
Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025] - Trefis
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
Pfizer CEO says US pharma industry needs to collaborate with China - Reuters
Lobbying Update: $30,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (PFE) Faces Continued Losses Despite Bullish Analyst Rati - GuruFocus
Is Pfizer’s Latest Drug Pricing Deal a Turning Point for 2025 Valuation? - simplywall.st
Pfizer CEO Urges US-China Collaboration In Pharma; Stock Drops For 7th Day As Traders Hold For Dividend Payout - Stocktwits
Pfizer (PFE) Receives a Buy from BMO Capital - The Globe and Mail
Pfizer Seeks Expanded Use Approval For Breast Cancer Drug - Benzinga
Pfizer's (PFE) Tukysa Achieves Key Milestone in Breast Cancer Tr - GuruFocus
Pfizer (PFE) Receives a Hold from Bernstein - The Globe and Mail
Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy - Seeking Alpha
Pfizer (PFE) Reports Positive Results from Key Breast Cancer Tri - GuruFocus
Pfizer Says Tukysa Combination as First-Line Maintenance Meets Main Goal in Breast Cancer Trial - MarketScreener
Tukysa combination significantly improves progression-free survival as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial - MarketScreener
Pfizer’s breast cancer drug shows promise in first-line treatment - Investing.com
Pfizer’s breast cancer drug shows promise in first-line treatment By Investing.com - Investing.com India
Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025] - Trefis
Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock - Yahoo Finance
Trump's AstraZeneca Deal Echoes Pfizer Pact. Big Pharma's Political Headaches Are Easing. - Barron's
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail
Pfizer Reaches Agreement with U.S. Government to Lower Drug Costs - Contract Pharma
Lawsuits Claim Pfizer Failed to Warn of Brain Tumor Risk From Birth Control Shot - Truthout
Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices - Medical Daily
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Pfizer stock rises as BMO Capital reiterates Outperform rating - Investing.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud
Verdence Capital Advisors LLC Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer To Highlight Advancements In Respiratory Health And Infectious Disease Research At IDWeek 2025 - TradingView
Griffin Asset Management Inc. Grows Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer to present infectious disease data at IDWeek 2025 - Investing.com
Concurrent Investment Advisors LLC Purchases 20,663 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 - Business Wire
Vanguard Personalized Indexing Management LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, Inc. (PFE) Stock Analysis: Exploring the 16% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Estrogen Blockers Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Novartis AG, AstraZeneca PLC - openPR.com
IP Group in line for future royalties from Pfizer’s drug deal - Proactive Investors
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):